Kevin Marks, Ph.D.

Dr. Kevin Marks brings two decades of experience as a cancer drug hunter to his role at Delphia as president, CEO and member of the board of directors. Kevin co-founded and launched Delphia in 2022 while an entrepreneur-in-residence at GV (Google Ventures).

Previously, Kevin served as head of oncology drug discovery at Novartis Institutes for Biomedical Research. There, he served on the oncology leadership team and led a broad team of oncology scientists to advance an innovative portfolio of first-in-class medicines. Prior to that, he was vice president and head of biology at Agios Pharmaceuticals, where he led research spanning oncology, immuno-oncology and rare genetic diseases. Kevin joined as one of the initial employees at Agios, where he championed advances in science, organization and culture over a nearly 12-year tenure. During this time, he contributed to three medicines (IDHIFA, TIBSOVO and PYRUKYND), which progressed from concept to clinic to FDA approval. Before Agios, Kevin served in scientific roles at Makoto Life Sciences and Curis, where he applied chemical biology approaches to drug previously intractable targets.

Kevin holds a B.A. in cell biology from Cornell University and a Ph.D. in molecular pharmacology from Stanford University.